Trial intelligence / Profile preview

Ciprofloxacin target attainment during neutropenia prophylaxis in hematologic malignancy patients

NL-OMON20490Recruiting

Sponsor
Amsterdam University Medical Center
Start
Feb 2019
Modality
Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
1
01

Overview

Open-label, single-arm trial of ciprofloxacin in chemotherapy-induced neutropenia (CIN) and hematopoietic malignancies, sponsored by Amsterdam University Medical Center. Started Feb 2019; status: recruiting.

02

Drugs

ciprofloxacin
03

Conditions

chemotherapy-induced neutropenia (CIN)hematopoietic malignancies

Beyond the preview

Go deeper on NL-OMON20490.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NL-OMON20490.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call